الدور المناعي ل sFas و أثره على المعالجة الكيمائية و الإشعاعية لدى مريضات سرطان الثدي السوريات

الملخص EN

The study aimed to assess the clinical usefulness of determination of serum Fas (sFas) levels in breast cancer patients treated with chemotherapy and radiotherapy, by determining its serum concentration before and after therapy.

And assessing its role as a prognostic marker for recurrence and matastasis.

Serum sFas plays an important role in cancer progression by inhibiting Fas mediated-apoptosis.

This is a mechanism of tumor immune escape in cancer patients.

The study included 85 women: 60 breast cancer patients (44 patients with I&II stages and 16 patients with III stage; mean age 50.2 years), and a control group: 25 apparently healthy women; mean age 32.3 years.

First serum sample was collected after the patient had undergone to a surgical operation and before she underwent to any other treatments.

Second sample was collected after a week of the patient had finished chemotherapy and radiotherapy treatments.

Serum sFas levels were determined by sandwich ELISA method.

Through the next twelve months after treatments, the patients were followed up to assess their clinical cases and to diagnose recurrence and metastasis states, according to the physicians.

It was noted three patients (5%) with recurrence and five patients (8.33%) with metastasis, while the other 52 patients (86.66%) had good clinical cases, through the follow up period.

The serum Fas levels were significantly higher in the patients group than in the control group (p<0.01).The levels of sFas were significantly higher after radiotherapy and chemotherapy than before therapy (p<0.001).

At the end of therapy, sFas levels were significantly higher in patients with recurrence and metastasis than in patients with none (p<0.01).

Our results may support that determination of serum Fas levels can be useful in clinical practice, as a prognostic marker.

So it can be used in predicting recurrence and metastasis in treated breast cancer patients.